Focused Power Ultrasound Mediated Inferior Perirenal Adipose Tissue Modification Therapy for Essential Hypertension

A trial with no phase registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 103 participants.

Also called NCT05049096

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 103 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05049096
Other papers using this trial's data
  • Perirenal fat as a potential marker and therapeutic target for metabolic syndrome: insights from a multicenter randomized controlled trial Frontiers in endocrinology, 2025 DOI, PubMed 40487756, PMC12140993 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT05049096. Randomized; triple masking; primary purpose treatment. Start 2021-11-01 (actual); primary completion 2023-11-20 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Focused Power Ultrasound Mediated Inferior Perirenal Adipose Tissue Modification Therapy for Essential Hypertension
Acronym
PARADISE-HTN
Condition
Hypertension
Condition
Blood Pressure
Condition
Cardiovascular Diseases
Intervention (Device)
focused power ultrasound mediate inferior perirenal adipose tussue modification
Intervention (Device)
sham-control group
Lead sponsor
The First Affiliated Hospital with Nanjing Medical University (class: other)

Record details

Record id
cardio:ct-nct05049096
Content hash
d7faeffd1c1ee0a74a779f1156a1c416ed8bdfe07bf0173d2bb2fbeb26501f37